(Q37229788)

19 August 2017

1 reference

title

Leukocytapheresis for the treatment of IBD. (English)

1 reference

19 August 2017

author name string

Fridrik Thor Sigurbjörnsson

series ordinal

1

1 reference

19 August 2017

Ingvar Bjarnason

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

29 July 2008

1 reference

Nature Reviews Gastroenterology & Hepatology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

509-516

1 reference

Innovative therapeutics for inflammatory bowel disease

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Treatment of inflammatory bowel disease: a review of medical therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Improved on-line thoracic duct drainage for lymphocytapheresis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Efficacy of filtration leukocytapheresis on rheumatoid arthritis with vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Therapeutic leukocytapheresis for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Centrifugal leukocyte apheresis for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Treating ulcerative colitis without medications--"look mom, no drugs!"

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1209

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP1209

1 reference

19 August 2017

1 reference